IESE (España)
-
Aster Capital and the Secureq Deal (B)
Menden, Lenka; Johnson, RobCase E-167-EEntrepreneurship, FinanceThe case discusses the dilemma a French venture capitalist faces in a portfolio company that is a fast-growing industry leader yet is being held back by co-investors whose objectives are different from that of the venture capitalist. The case also addresses issues involved in government-sponsored investment incentive schemes.Starting at €5.74
-
Aster Capital and the Secureq Deal (A)
Menden, Lenka; Johnson, Rob; Liechtenstein, HeinrichCase E-151-EFinanceThis case describes the attempt by Aster Capital, a Paris-based clean-technology-focused venture capital fund, to exit an investment in its portfolio company Secureq, a France-based security software vendor. Aster Capital invested in Secureq in 2004 from its first fund, SEV1 (raised in 2000). Since 2009, this fund had been in the process of divestment. At the time of the case (spring 2011), Jean-Marc Bally, managing director at Aster, felt that a...Starting at €8.20
-
The Clinton Economic Program
Canals, JordiCase ASE-297-EEconomicsThis case sets the ground for a discussion of the main problems of the US economy in the 1990s and the new economic plan designed by President Clinton.Starting at €8.20
-
El programa económico de Clinton
Canals, JordiCase ASE-297EconomicsEste caso prepara el terreno para una discusión de los principales problemas de la economía de Estados Unidos en los años noventa y el nuevo plan económico diseñado por el presidente Clinton.Starting at €8.20
-
La reducción de impuestos del presidente Kennedy
Canals, JordiCase ASE-208EconomicsEl caso permite discutir la efectividad de la política fiscal para estimular la actividad económica. [Es una versión abreviada y modificada del caso The Tax Cut of 1964 (ASE-24)].Starting at €8.20
-
Glaxo: The acquisition of Wellcome
Canals, Jordi; Bardolet Urgellès, DavidCase ASE-386-EEconomicsThis case describes the changes in the world pharmaceutical industry in 1995 and presents the challenges for Glaxo (the leading European pharmaceutical firm) and the potential acquisition of Wellcome. This decision will differ from other acquisitions made by firms like Merck, oriented towards vertical integration and control over the distribution network. The main topics that the case covers are: industry analysis; value chain analysis; positioni...Starting at €8.20